Relay Therapeutics Reports Material Agreements
Ticker: RLAY · Form: 8-K · Filed: Jun 4, 2025 · CIK: 1812364
| Field | Detail |
|---|---|
| Company | Relay Therapeutics, Inc. (RLAY) |
| Form Type | 8-K |
| Filed Date | Jun 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, termination, 8-K
TL;DR
Relay Therapeutics filed an 8-K detailing both new material agreements and terminations.
AI Summary
On June 3, 2025, Relay Therapeutics, Inc. reported the entry into a material definitive agreement and the termination of a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Cambridge, Massachusetts, filed this 8-K report under the 1934 Act.
Why It Matters
This filing indicates significant changes in Relay Therapeutics' contractual relationships, which could impact its ongoing operations and strategic partnerships.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and terminations, which can signal significant shifts in business strategy or partnerships that carry inherent risks.
Key Numbers
- 001-39385 — Commission File Number (Identifies the company's filing with the SEC.)
- 47-3923475 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Relay Therapeutics, Inc. (company) — Registrant
- June 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Cambridge, Massachusetts (location) — Address of Principal Executive Offices
- 001-39385 (identifier) — Commission File Number
- 1934 Act (regulation) — SEC Act
FAQ
What specific material definitive agreement was entered into by Relay Therapeutics?
The filing states the entry into a material definitive agreement but does not provide specific details within the provided text.
What material definitive agreement was terminated by Relay Therapeutics?
The filing indicates the termination of a material definitive agreement, but specific details are not included in the provided text.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated June 3, 2025.
In which state is Relay Therapeutics, Inc. incorporated?
Relay Therapeutics, Inc. is incorporated in Delaware.
What is the address of Relay Therapeutics' principal executive offices?
The principal executive offices are located at 60 Hampshire Street, Cambridge, Massachusetts, 02139.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding Relay Therapeutics, Inc. (RLAY).